Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: Do we need more evidence?

Retina

Volumn 32, Issue 8, 2012, Pages 1443-1445

  Lai, Timothy Y Y ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b 2010 Retina and Macula Centre   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; VERTEPORFIN;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE COMPARISON; HUMAN; LASER COAGULATION; LOADING DRUG DOSE; MULTICENTER STUDY (TOPIC); MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINA MACULA TRANSLOCATION; RETINA PIGMENT DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC);

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AXIAL LENGTH, EYE; CHOROIDAL NEOVASCULARIZATION; HUMANS; MYOPIA, DEGENERATIVE; OFF-LABEL USE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84865717269     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31826956e4     Document Type: Review

References (26)

1. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet 2012; 379:1739-1748.
2. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore 2004;33:27-33. (Pubitemid 38478105)
3. Moriyama M, Ohno-Matsui K, Hayashi K, et al. Topographic analyses of shape of eyes with pathologic myopia by highresolution three-dimensional magnetic resonance imaging. Ophthalmology 2011;118:1626-1637.
4. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
5. Lai TY, Fan DS, Lai WW, Lam DS. Peripheral and posterior pole retinal lesions in association with high myopia: a crosssectional community-based study in Hong Kong. Eye 2008;22: 209-213. (Pubitemid 351266459)
6. Liu HH, Xu L, Wang YX, et al. Prevalence and progression of myopic retinopathy in Chinese adults: the Beijing Eye Study. Ophthalmology 2010;117:1763-1768.
7. Avila MP, Weiter JJ, Jalkh AE, et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-1581. (Pubitemid 15197032)
8. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 2003;87:570-573. (Pubitemid 36535327)
9. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103:1241-1244. (Pubitemid 26282507)
10. Secretan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7: 307-316. (Pubitemid 28042043)
11. Tabandeh H, Flynn HW Jr, Scott IU, et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999;106:2063-2067. (Pubitemid 30194225)
12. Ohno-Matsui K, Shimada N, Yasuzumi K, et al. Long-term development of significant visual field defects in highly myopic eyes. Am J Ophthalmol 2011;152:256-265.e1.
13. Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 2000;118:344-350. (Pubitemid 30152374)
14. Hamelin N, Glacet-Bernard A, Brindeau C, et al. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am J Ophthalmol 2002;133: 530-536. (Pubitemid 34258062)
15. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108:841-852.
16. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-673. (Pubitemid 36520061)
17. Parodi MB, Da Pozzo S, Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol Scand 2007;85:50-54. (Pubitemid 46140156)
18. Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 2012. Apr 4 [Epub ahead of print].
19. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495-525.
20. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012;32:1539-1546.
21. Ruiz-Moreno J, Lopez-Galvez MI, Gomez-Ulla F, et al. Myopic choroidal neovascularization. Ophthalmology 2012;118: 2521-2522.
22. Arias L, Caminal JM, Casas L, et al. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:1636-1641.
23. Wakabayashi T, Ikuno Y, Gomi F. Different dosing of intravitreal bevacizumab of choroidal neovascularization because of pathologic myopia. Retina 2011;31:880-886.
24. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye 2012;26: 1004-1011.
25. Shimada N, Ohno-Matsui K, Hayashi K, et al. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 2011;55: 378-382.
26. Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009;29:1062-1066.